In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses real-world data (RWD) collected from a large series of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) that received CAR-T cell therapy, which confirmed the efficacy, safety, and response rates of this therapy. Prof. Mohty also highlights that further research is needed to determine whether patients receiving CAR-T therapy also require allogeneic stem cell transplantation (alloSCT). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.